185 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by CVA Family Office LLC

CVA Family Office LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQVFree Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 185 shares of the medical research company’s stock, valued at approximately $43,000.

A number of other large investors have also recently bought and sold shares of IQV. Parkside Financial Bank & Trust boosted its holdings in IQVIA by 19.6% during the second quarter. Parkside Financial Bank & Trust now owns 293 shares of the medical research company’s stock worth $66,000 after purchasing an additional 48 shares during the last quarter. Laurel Wealth Advisors LLC grew its stake in IQVIA by 1.1% in the 3rd quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company’s stock valued at $927,000 after buying an additional 50 shares during the last quarter. Private Advisor Group LLC lifted its position in IQVIA by 1.2% during the third quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company’s stock worth $948,000 after acquiring an additional 56 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its holdings in shares of IQVIA by 1.6% during the third quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock worth $702,000 after acquiring an additional 56 shares during the period. Finally, Penserra Capital Management LLC increased its stake in shares of IQVIA by 6.1% during the fourth quarter. Penserra Capital Management LLC now owns 971 shares of the medical research company’s stock worth $198,000 after purchasing an additional 56 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on IQV. UBS Group increased their price objective on IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Barclays increased their target price on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Finally, BTIG Research started coverage on IQVIA in a research report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $256.80.

Check Out Our Latest Report on IQVIA

IQVIA Price Performance

Shares of NYSE:IQV opened at $252.89 on Friday. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The company has a market cap of $45.90 billion, a price-to-earnings ratio of 34.69, a PEG ratio of 2.40 and a beta of 1.51. The firm has a 50 day simple moving average of $236.43 and a 200 day simple moving average of $217.77.

IQVIA (NYSE:IQVGet Free Report) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. The company had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. IQVIA’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.54 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In related news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the transaction, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,285 shares of company stock worth $10,331,003. Insiders own 1.60% of the company’s stock.

IQVIA Company Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Stories

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.